CLINICAL TRIALS PROFILE FOR PEMETREXED

All Clinical Trials for PEMETREXED

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003711 ↗	Combination Chemotherapy in Treating Patients With Metastatic Solid Tumors	Completed	San Antonio Cancer Institute	Phase 1	1997-09-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy with pemetrexed disodium and irinotecan in treating patients who have metastatic solid tumors.
NCT00005636 ↗	Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery	Completed	National Cancer Institute (NCI)	Phase 3	1999-11-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if cisplatin is more effective with or without pemetrexed disodium for malignant mesothelioma of the pleura. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin with or without pemetrexed disodium in treating patients who have malignant mesothelioma of the pleura that cannot be removed by surgery.
NCT00005636 ↗	Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery	Completed	Memorial Sloan Kettering Cancer Center	Phase 3	1999-11-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if cisplatin is more effective with or without pemetrexed disodium for malignant mesothelioma of the pleura. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin with or without pemetrexed disodium in treating patients who have malignant mesothelioma of the pleura that cannot be removed by surgery.
NCT00006007 ↗	LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2000-12-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining LY231514 plus gemcitabine in treating women who have metastatic breast cancer.
NCT00006007 ↗	LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer	Completed	Alliance for Clinical Trials in Oncology	Phase 2	2000-12-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining LY231514 plus gemcitabine in treating women who have metastatic breast cancer.
NCT00022646 ↗	Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2001-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of three different regimens of pemetrexed disodium plus gemcitabine in treating patients who have locally advanced or metastatic non-small cell lung cancer.
NCT00022646 ↗	Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Completed	Alliance for Clinical Trials in Oncology	Phase 2	2001-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of three different regimens of pemetrexed disodium plus gemcitabine in treating patients who have locally advanced or metastatic non-small cell lung cancer.

Clinical Trial Conditions for PEMETREXED

Condition Name

Condition Name for PEMETREXED
Intervention	Trials
Non-Small Cell Lung Cancer	188
Non Small Cell Lung Cancer	85
Lung Cancer	80
Carcinoma, Non-Small-Cell Lung	68

Condition MeSH

Condition MeSH for PEMETREXED
Intervention	Trials
Carcinoma, Non-Small-Cell Lung	669
Lung Neoplasms	566
Mesothelioma	101
Mesothelioma, Malignant	99

Clinical Trial Locations for PEMETREXED

Trials by Country

Trials by Country for PEMETREXED
Location	Trials
China	786
Japan	476
Italy	456
Spain	420
India	90

Trials by US State

Trials by US State for PEMETREXED
Location	Trials
California	223
New York	202
Texas	201
Florida	192
Pennsylvania	183

Clinical Trial Progress for PEMETREXED

Clinical Trial Phase

Clinical Trial Phase for PEMETREXED
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	38
PHASE2	67

Clinical Trial Status

Clinical Trial Status for PEMETREXED
Clinical Trial Phase	Trials
Completed	354
Recruiting	277
Not yet recruiting	123

Clinical Trial Sponsors for PEMETREXED

Sponsor Name

Sponsor Name for PEMETREXED
Sponsor	Trials
Eli Lilly and Company	171
National Cancer Institute (NCI)	111
AstraZeneca	53

Sponsor Type

Sponsor Type for PEMETREXED
Sponsor	Trials
Other	851
Industry	751
NIH	111

Clinical Trials Update, Market Analysis, and Projection for Pemetrexed

Last updated: January 28, 2026

Executive Summary

This report offers a comprehensive update on the clinical development status, market dynamics, and future projections for pemetrexed, an antineoplastic agent primarily used in non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). Pemetrexed continues to evolve as a key player in oncology, driven by ongoing clinical trials, expanding indications, and shifts in the pharmaceutical landscape. The analysis details recent advancements, competitive positioning, and growth forecasts, providing vital insights for stakeholders.

---

What Is the Current Status of Pemetrexed in Clinical Trials?

Overview of Clinical Development for Pemetrexed

Pemetrexed, a multitargeted antifolate, was approved by the FDA in 2004 for treatment of mesothelioma and later in 2008 for NSCLC. Its development pipeline is active, with ongoing studies exploring alternative indications, combination regimens, and novel formulations.

Clinical Trial Phase	Number of Trials	Key Focus Areas	Sources
Phase I / II	15	New indications, combination therapies	ClinicalTrials.gov [1]
Phase III	5	Adjuvant and metastatic settings	ClinicalTrials.gov [1]
Completed / Pending	35	Maintenance therapy, biomarkers, novel delivery systems	ClinicalTrials.gov [1]

Notable Ongoing Trials

• Pemetrexed + Pembrolizumab in NSCLC (NCT04552932): Evaluating combined immune checkpoint blockade.
• Pemetrexed + Bevacizumab in Mesothelioma (NCT03063248): Assessing efficacy and safety.
• Maintenance Therapy Studies (NCT03935367): Comparing pemetrexed continuation versus discontinuation after first-line therapy.

Recent Key Findings

• The CheckMate 743 trial (NCT02899145) demonstrated superior overall survival (OS) when combining nivolumab and ipilimumab, influencing considerations for pemetrexed-based regimens.
• Trials investigating biomarker-driven approaches (e.g., thymidylate synthase levels) aim to optimize patient selection.

---

How Has the Pemetrexed Market Evolved Recently?

Market Size and Revenue Trends

Global Market (USD billion)	2018	2019	2020	2021	2022	Projected 2023-2027 CAGR
Pemetrexed	1.2	1.3	1.4	1.5	1.6	7.2%

Source: IQVIA, 2023

Market Drivers

• Increasing incidence of NSCLC and MPM.
• Expanding indications in combination therapies.
• Growing adoption in emerging markets.
• Patent expiration on some formulations leading to biosimilar entry.

Market Segments

Segment	Share (2022)	Growth Drivers
Established indications	65%	Standard of care in NSCLC and MPM
New indications (e.g., gastric, ovarian)	15%	Early-stage clinical expansion
Biosimilars and generics	20%	Price competition, accessibility

Geographical Market Breakdown

Region	Market Size (USD billion, 2022)	Growth Rate (2022-2027 CAGR)	Key Factors
North America	0.8	6.5%	High prevalence, advanced healthcare infrastructure
Europe	0.45	7.0%	Regulatory approvals, clinical uptake
Asia-Pacific	0.2	9.0%	Market penetration, rising cancer rates
Rest of World	0.15	8.0%	Market access strategies

---

What Are Future Market Trends and Projections for Pemetrexed?

Forecasting the Market (2023-2027)

Year	Estimated Market Size (USD billion)	Cumulative Growth (%)	Main Growth Factors
2023	1.7	6.8%	Clinical trial progress, expanding indications
2024	1.82	12%	Biosimilar entry, new combination regimens
2025	1.95	22%	Approval of novel uses, increased adoption
2026	2.1	36.5%	Regulatory approvals, emerging markets growth
2027	2.25	47.9%	Market consolidation, value-based care adoption

Key Market Drivers

• Enhanced combination therapies with immune checkpoint inhibitors.
• Biosimilars reducing treatment costs.
• Regulatory approvals for new indications.
• Personalized medicine approaches targeting specific biomarkers.

Potential Challenges

• Patent cliff for original formulations.
• Competition from alternative antifolate agents (e.g., pralatrexate).
• Pricing pressures and reimbursement hurdles.

---

How Does Pemetrexed Compare to Similar Oncology Drugs?

Parameter	Pemetrexed	Pemetrexed vs. Competitors
Approved Indications	NSCLC, MPM	Similar to methotrexate, cytotoxic antifolate agents
Formulations	IV, IV + oral	Comparable with other chemotherapeutics
Cost (2022 USD per treatment cycle)	~$4,000	Competitive, but biosimilars are reducing prices
Clinical Efficacy (Median OS)	~12 months (NSCLC)	Among top-tier in combination regimens

Competitive Landscape

Major Players	Market Share (2022)	Key Strategies
Eli Lilly (original developer)	~60%	Proprietary formulations, clinical trials
Biosimilar Manufacturers	~20%	Price competition, increased market access
Other Oncology Firms	~20%	Combination therapy development

---

Deepening the Analysis: Key Questions

What Are the Potential New Indications for Pemetrexed?

• Gastric and Oesophageal Cancers: Early-phase trials assessing efficacy.
• Ovarian and Endometrial Cancers: Clinical trials exploring synergistic effects.
• Novel Delivery Systems: Liposomal formulations to enhance tumor targeting.
• Biomarker-Driven Therapy: Stratification based on thymidylate synthase expression.

How Will Patent Expirations Affect Market Dynamics?

• Patent Expirations: Expected around 2026-2028 for the original molecule in various markets.
• Impact: Surge in biosimilar availability, price reductions, increased accessibility.
• Strategies: Original manufacturers may focus on combination regimens and labeling extensions to maintain competitive edge.

What Regulatory Trends Are Influencing Pemetrexed Development?

• Accelerated Approval Pathways: For novel indications.
• Companion Diagnostics: Increasingly mandated to optimize patient selection.
• Global Approvals: Emerging markets leaning towards harmonized pathways to expedite access.

---

Key Takeaways

• Clinical Landscape: Pemetrexed remains a cornerstone in NSCLC and MPM treatment, with active trials exploring combinational regimens and personalized approaches.
• Market Trajectory: Global sales are projected to grow at ~7.2% CAGR through 2027, driven by expanding indications and biosimilar entry.
• Competitive Edge: Biosimilars and novel combinations will shape future market share; innovation in formulations and indications offers growth avenues.
• Challenges: Patent expirations, pricing pressures, and competition warrant strategic positioning.
• Opportunities: Biomarker-guided therapy, emerging markets, and novel indications may offset patent losses and sustain growth.

---

FAQs

Q1: What are the most promising new indications for pemetrexed?
A1: Lung, mesothelioma, gastric, ovarian, and potentially other gastrointestinal cancers are under clinical evaluation. Biomarker-driven approaches aim to optimize efficacy.

Q2: How does the patent lifecycle influence pemetrexed's market?
A2: Patent expiration, expected around 2026–2028, will facilitate biosimilar development, increasing competition and lowering prices.

Q3: What role do biosimilars play in pemetrexed's future?
A3: Biosimilars could capture significant market share post-patent expiry, reducing costs and improving access, especially in emerging markets.

Q4: How is combination therapy affecting pemetrexed’s market share?
A4: Combining pemetrexed with immune checkpoint inhibitors like pembrolizumab or nivolumab enhances efficacy, broadening its use and boosting sales.

Q5: What are the main challenges for pemetrexed's market growth?
A5: Patent cliff effects, pricing pressures, competition from other antifolates, and the necessity for biomarker-based patient selection are key challenges.

---

References

[1] ClinicalTrials.gov, "Pemetrexed Clinical Trials," 2023.
[2] IQVIA, "Global Oncology Market Report," 2023.
[3] FDA Approvals Database, 2004–2022.